Positions

Overview

  • Introduction:

    Dr. Ahmed Elkhanany is an Assistant Professor of Medicine in the Division of Hematology & Oncology at the University of Alabama at Birmingham. He received his Hematology and Oncology training at Roswell Park Cancer Center in New York, where his research focused on Breast cancer cells make up, and how they differ by race/ethnicity.
    Research:

    His main interest remains in genomic understanding of Breast cancer driver factors and developing novel agents that can combat the aggressive forms of the disease.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+T-Cell Exhaustion 2021
    2021 Disparities in Breast Cancer Associated With African American Identity..  American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting.  41:e29-e46. 2021
    2021 Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021 2021
    2020 Contribution of immune cells to glucocorticoid receptor expression in breast cancer.  International Journal of Molecular Sciences.  21:1-17. 2020
    2020 Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 1.2020 featured updates to the NCCN guidelines 2020
    2019 Primary and secondary breast angiosarcoma: single center report and a meta-analysis.  Breast Cancer Research and Treatment.  178:523-533. 2019
    2018 Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.  Breast Cancer Research and Treatment.  167:89-99. 2018
    2015 Clinical correlates of common corneal neovascular diseases: A literature review.  International Journal of Ophthalmology.  8:182-193. 2015
    2015 Cocaine induced pleural and pericardial effusion syndrome. 2015
    2014 GAIP interacting protein C-Terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways.  PLoS ONE.  9. 2014
    2013 Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo.  International Journal of Cancer.  132:1201-1212. 2013

    Principal Investigator On

    Investigator On

  • A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases  awarded by Dana-Farber Cancer Institute
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE R20-080  awarded by ECOG-ACRIN CANCER RESEARCH GROUP
  • Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect  awarded by University of Wisconsin-Madison
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by DAIICHI SANKYO, INC.
  • Private Grant  awarded by LILLY USA, LLC
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by CELCUITY
  • Private Grant  awarded by CELCUITY
  • Private Grant  awarded by FAETH THERAPEUTICS, INC
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE
  • UAB 1428 – A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer (HOG Trial)  awarded by HOOSIER CANCER RESEARCH NETWORK
  • UAB 17127-A Phase 1b Trial of Fulvestrant, Palbociclib (CDK4/6 inhibitor) and Erdafitinib (JNJ-42756493, Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2–/FGFR-Amplified Metastatic Breast Cancer (MBC)  awarded by VANDERBILT UNIVERSITY
  • XUAB 2167 - A Phase II Circulating Tumor DNA Enriched, Gnomically Directed Post-Neoadjuvant Trial for Patients with Residual Triple Negative Breast Cancer (PERSEVERE): HCRN BRE18-334  awarded by HOOSIER CANCER RESEARCH NETWORK
  • XUAB2147-Phase I/II Study of Stereotactic Radiosurgery with Concurrent Administration of DNA Damage Response (DDR) Inhibitor (Olaparib) Followed by Adjuvant Combination of Durvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases  awarded by HOOSIER CANCER RESEARCH NETWORK
  • [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Women with Newly Diagnosed Metastatic Breast Cancer (R20-146)  awarded by ECOG-ACRIN CANCER RESEARCH GROUP

    • Education And Training

  • Doctor of Medicine, Alexandria University 2011

    • Full Name

  • Ahmed Elkhanany